Next Article in Journal / Special Issue
Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment
Previous Article in Journal
The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma
Previous Article in Special Issue
SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview

The Tumor Microenvironment in Colorectal Cancer Therapy

Department of Medical Oncology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain
Translational Genomics and Targeted Therapeutics in Solid Tumors Group, Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
Department of Medicine, University of Barcelona, 08036 Barcelona, Spain
Networking Center for Biomedical Research in Hepatic and Digestive Diseases (CIBER-EHD), Instituto de Salud Carlos III, 28029 Madrid, Spain
Laboratory of Cell Signaling and Cancer, Institute for Molecular Biology, Science Research Council (CSIC), 08036 Barcelona, Spain
Authors to whom correspondence should be addressed.
Cancers 2019, 11(8), 1172;
Received: 12 July 2019 / Revised: 26 July 2019 / Accepted: 9 August 2019 / Published: 14 August 2019
(This article belongs to the Collection Drug Resistance and Novel Therapies in Cancers)
PDF [2667 KB, uploaded 14 August 2019]
  |     |  


The current standard-of-care for metastatic colorectal cancer (mCRC) includes chemotherapy and anti-angiogenic or anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, even though the addition of anti-angiogenic agents to backbone chemotherapy provides little benefit for overall survival. Since the approval of anti-angiogenic monoclonal antibodies bevacizumab and aflibercept, for the management of mCRC over a decade ago, extensive efforts have been devoted to discovering predictive factors of the anti-angiogenic response, unsuccessfully. Recent evidence has suggested a potential correlation between angiogenesis and immune phenotypes associated with colorectal cancer. Here, we review evidence of interactions between tumor angiogenesis, the immune microenvironment, and metabolic reprogramming. More specifically, we will highlight such interactions as inferred from our novel immune-metabolic (IM) signature, which groups mCRC into three distinct clusters, namely inflamed-stromal-dependent (IM Cluster 1), inflamed-non stromal-dependent (IM Cluster 2), and non-inflamed or cold (IM Cluster 3), and discuss the merits of the IM classification as a guide to new immune-metabolic combinatorial therapeutic strategies in mCRC. View Full-Text
Keywords: colorectal cancer; mCRC; tumor microenvironment (TME); tumor-infiltrating lymphocytes (TILs); angiogenesis; tumor metabolism colorectal cancer; mCRC; tumor microenvironment (TME); tumor-infiltrating lymphocytes (TILs); angiogenesis; tumor metabolism

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Pedrosa, L.; Esposito, F.; Thomson, T.M.; Maurel, J. The Tumor Microenvironment in Colorectal Cancer Therapy. Cancers 2019, 11, 1172.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top